Interleukin-12 in Treating Patients With Cancer in the Abdomen

This study has been completed.

Study NCT00003046 Information provided by M.D. Anderson Cancer Center

First Received: November 1, 1999 Last Updated: August 4, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2001
Primary Completion Date:	October 2001 (Final data collection date for primary outcome measure)

Publications:

Lenzi R, Kudelka AP, Veschraegen C, et al.: Intraperitoneal (IP) bioimmunologic responses in patients with ovarian and gastrointestinal cancers at a low toxicity dosing schedule of IP recombinant interleukin-12 (rhIL-12). [Abstract] Proc Am Assoc Cancer Res 40: A3778, 573, 1999.